Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.47 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.47 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4279128 | 1.00 | AR (0.54) | ARALDH1A1MAPTPARP15PARP10 | |
| SCHEMBL14263051 | 0.86 | AR (0.54) | ARALDH1A1MAPTMMP2RAB9A | |
| SCHEMBL12378041 | 0.86 | AR (0.54) | ARALDH1A1MAPTMMP2RAB9A | |
| SCHEMBL13574311 | 0.86 | AR (0.54) | ARALDH1A1MAPTMMP2RAB9A | |
| SCHEMBL13520469 | 0.86 | AR (0.54) | ARALDH1A1MAPTMMP2RAB9A | |
| SCHEMBL18677371 | 0.84 | AR (0.53) | ARALDH1A1MAPTMMP2RAB9A | |
| SCHEMBL18677477 | 0.84 | AR (0.53) | ARALDH1A1MAPTMMP2RAB9A | |
| SCHEMBL17643998 | 0.84 | AR (0.53) | ARALDH1A1MAPTMMP2RAB9A | |
| SCHEMBL13523302 | 0.83 | AR (0.52) | ARALDH1A1MAPTMMP2RAB9A | |
| SCHEMBL10062799 | 0.83 | AR (0.55) | ARALDH1A1MAPTMMP2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3147278-A1 | COMPOUND FOR TREATING BREAST CANCER AND PROGESTIN-DEPENDENT CONDITIONS | University of Tennessee Research Foundation (US) | 2017-03-29 | — | — | EP | disclosed |
| EP-2038252-B1 | SUBSTITUTED ACYLANILIDES AND METHODS OF USE THEREOF | UNIV TENNESSEE RES FOUNDATION (US) | 2016-11-02 | — | — | EP | disclosed |
| WO-2016061534-A1 | METHODS OF TREATING UROLOGICAL DISORDERS USING SARMs | GTX, INC. (US) | 2016-04-21 | — | — | WO | disclosed |
| WO-2014011220-A2 | A METHOD OF TREATING ANDROGEN RECEPTOR (AR)-POSITIVE BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATOR (SARMS) | GTX, INC. (US) | 2014-01-16 | — | — | WO | disclosed |
| WO-2013067170-A1 | PHARMACEUTICAL COMPOSITIONS OF SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | GTX, INC. (US) | 2013-05-10 | — | — | WO | disclosed |